The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what Peptides are starting to move back into the conversation., After years of restriction under the FDAs 503A Category 2 list, were now seeing momentum toward re evaluation and potential reintroduction FDA considers adding a dozen peptides to its bulk drug compounding list RAPS BPC 157 FDA approval status 2026: Is it legal? Veedma FDA Moves to Exclude Semaglutide, Tizerpatide, and Liraglutide from 503B Bulk Substances List Lengea FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner